

## Primary Hyperparathyroidism Committee meeting 13

**Date:** 29/01/2019

**Location:** NGC Boardroom

**Minutes:** Confirmed

<b>Committee members present:</b>		
Jonathan Mant (Chair) (JM)		(Present for notes 1 – 4)
Terry Aspray (TA)		(Present for notes 1 – 4)
Julie Cox (JC)		(Present for notes 1 – 3.2)
Parijat De (PD)		(Present for notes 1 – 4)
Joy Foster (JF)		(Present for notes 1 – 4)
Neil Gittoes (NG)		(Present for notes 1 – 4)
Imran Jawaid (IJ)		(Present for notes 1 – 4)
Fausto Palazzo (FP)		(Present for notes 1 – 4)
Peter Selby (PS)		(Present for notes 1 – 4)
Anthony Skene (AS)		(Present for notes 1 – 4)
Nicholas Thomson (NT)		(Present for notes 1 – 4)
<b>In attendance:</b>		
Katie Broomfield (KB)	Project Manager	(Present for notes 1 – 4)
Emma Cowles (EC)	Senior Health Economist	(Present for notes 1 – 3.3)
Gareth Haman (GH)	Senior Medical Editor, NICE	(Present for notes 1 – 4)
Ian Mather (IM)	Business Analyst	(Present for notes 1 – 4)
Sharangini Rajesh (SR)	Senior Research Fellow	(Present for notes 1 – 4)
Nick Staples (NS)	Guideline Commissioning Manager, NICE	(Present for notes 1 – 3.2)
Sharon Swain (SS)	Associate Director/Guideline Lead, NGC	(Present for notes 1 – 4)
Melina Vasileiou (MV)	Research Fellow	(Present for notes 1 – 4)

<b>Apologies:</b>	
Jill Cobb (JC)	Information Specialist, NGC
Judith McBride (JMB)	Senior Medical Editor, NICE

## 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the final meeting on primary hyperparathyroidism.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

## Introductions

## 2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to declare verbally any interests that have arisen since application. The following new interests were received for this meeting:

<b>Committee Declarations of Interest</b>			
N.B. The Chair and Committee members were recruited to this guideline using NICE DOI policy published Sept 2014.			
<b>Insert initials</b>	<b>Declaration</b>	<b>Classification (as per the NICE DOI policy wording*)</b>	<b>Chair's action</b>
NG	Advisory Board to UCB pharmaceuticals for a possible new drug for osteoporosis that as yet does not have marketing authorisation.	Direct financial non-specific	Declare and participate
JM	On advisory board for Bristol Myers Squibb on developments in detection of atrial fibrillation.	Direct financial non-specific	Declare and participate
NICE DOI policy classifications are: <ul style="list-style-type: none"><li>• Personal financial specific</li><li>• Personal financial non-specific</li><li>• Personal non-financial specific</li><li>• Personal non-financial non-specific</li><li>• Non-personal financial specific</li><li>• Non-personal financial non-specific</li></ul>			

The DOI register was made available to the Committee chair. The chair reviewed the DOI register and deemed that one of the original DOIs was in conflict with the agenda topics and clinical questions under discussion at the meeting:

FP: Based on the need for the committee member's expertise, in this instance NICE has confirmed that the individual can remain for discussion but participation is limited to responding to questions from the chair or other members.

### **3. Presentations and discussion**

3.1 The minutes and meeting notes from GC12 were confirmed to be an accurate record of the discussions.

3.2 The committee reviewed the consultation comments, discussed and edited draft responses and amended the recommendations where appropriate.

3.3 IM gave a presentation on resource impact.

3.4 The committee continued to review the consultation comments, discussed and edited draft responses and amended the recommendations where appropriate.

### **4. Any other business**

Next steps were discussed and action points agreed.